...
机译:急性缺血性卒中的静脉内重组组织纤溶酶原激活物和动脉尿激酶的顺序组合
Departments of Neurology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Diagnostic Radiology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Departments of Neurology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Diagnostic Radiology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Diagnostic Radiology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Diagnostic Radiology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Departments of Neurology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
Departments of Neurology, BK21 Projects for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea;
机译:台湾在批准静脉内组织纤溶酶原激活剂治疗前后,使用尿激酶进行局部动脉内溶栓治疗以治疗急性缺血性中风。
机译:在急性缺血性卒中中使用静脉内重组组织纤溶酶原激活剂对临床反应较差后,采用局部动脉内尿激酶进行抢救治疗。
机译:80岁以上急性缺血性卒中患者全剂量静脉内重组组织纤溶酶原激活剂静脉内溶栓治疗后的安全极限是多少?
机译:血管内干预后基于体素的急性缺血性卒中预后分类方法的比较
机译:急性缺血性卒中的灌注加权和弥散加权MR成像的组织特异性分析。
机译:静脉注重组织组织纤溶酶原激活剂和动脉内尿激酶中的连续组合急性缺血性卒中
机译:大容器闭塞的急性缺血性脑卒中中静脉内组织纤溶酶原激活剂的再生率和临床疗效